Breast cancer susceptibility gene 1 (BRCA1), mapped on chromosome 17q21, is implicated in the mechanisms of cellular DNA repair. Inactivation of this gene is involved in the development of many human cancers, including breast cancer. This study aimed to investigate the prognostic value of BRCA1 promoter hypermethylation and expression in breast cancer cases. Sixty-one breast cancers were examined for BRCA1 hypermethylation by methylation-specific polymerase chain reaction (PCR), and 45 paired normal breast tissues were analyzed for altered BRCA1 mRNA levels by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR). Aberrant methylation status in BRCA1 was detected in 15 of 61 cases (24.6%), while reduced expression was found in 7 of 45 (15.6%). BRCA1 hypermethylation was statistically associated with tumor grade III (p=0.04), a high frequency of stage IIB (p=0.02), and triple-negative phenotype (OR= 3.64, 95%CI =1.1-12.3, p=0.03) . Our findings indicated that BRCA1 promoter hypermethylation is a useful prognostic marker for breast cancer.
Introduction
Breast cancer susceptibility gene 1 (BRCA1) is mapped on chromosome 17q21; it encodes a multifunctional protein involved in DNA repair, cell-cycle check-point control, protein ubiquitinylation and chromatin remodeling (Miki et al., 1994; Ralhan et al., 2007) . Inactivation of this gene has been implicated in the development of many human cancers, including breast cancer.
Several studies have reported that BRCA1 genetic abnormality may lead to carcinogenesis, e. g., BRCA1 mutations account for about 40-45% of hereditary breast cancer patients (Rosen, 2013) . The loss of heterozygosity (LOH) at the BRCA1 locus was also more frequent among sporadic breast and ovarian cancers (Cropp et al., 1993; Saito et al., 1993; Ford et al., 1994) .
In the emerging epigenetic field, hypermethylation of CpG islands in the gene promoter region is an important mechanism leading to changes in gene expression, without altering genetic code (Paluszczak et al., 2006) . This study aimed to investigate the role of the BRCA1 hypermethylation epigenetic mechanism in Thai breast-cancer patients, to clarify the relevant prognostic biomarkers for breast cancer. We evaluated BRCA1 promoter hypermethylation, since, gene expression might play a role in the development of breast cancer, and the correlation of BRCA1 hypermethylation and BRCA1 cytosines remained unchanged. Bisulfite conversion used an EZ DNA Methylation Gold kit (Zymo Research, Orange, CA). One μg of DNA was treated with sodium bisulfite according to the manufacturer's protocol. The bisulfite-converted DNA was eluted in a total volume of 25 μl and stored at -20°C for later use.
RNA preparation and cDNA synthesis
Total RNA was extracted from 45 breast-tumor and their corresponding normal breast tissues using Trizol reagent, according to the instruction manual (Invitrogen, Carlsbad, CA, USA). mRNA was isolated by Oligotex mRNA purification kit (QIAGEN, Gmbh, Germany). Reverse transcription reactions were conducted according to the manufacturer's instructions, using the iScriptTM Select cDNA Synthesis Kit (Bio-Rad Laboratories, Inc, Hercules, CA) for reverse transcription-polymerase chain reaction (RT-PCR) (Invitrogen, Carlsbad, CA, USA).
Methylation analysis by methylation-specific PCR
The aberrant methylation status of the BRCA1 promoter region in 61 breast tumors was analyzed by methylation specific-PCR on sodium bisulfite modified DNA. The primers for the methylated and unmethylated sequences were FM-BRCA1-5' GGT TAA TTT AGA GTT TCG AGA GAC G 3'; RM-BRCA1-5' TCA ACG AAC TCA CGC CGC GCA ATC G 3'; FU-BRCA1-5' GGT TAA TTT AGA GTT TTG AGA GAT G 3'; RU-BRCA1-5' TCA ACA AAC TCA CAC CAC ACA ATC A 3'. (Baldwin et al., 2000) . The reactions were carried out in a total volume of 25 μl, containing 100 ng of bisulfitetreated DNA, 1X PCR buffer, 0.2 mM of each dNTP, 2.5 mM MgCl 2 , 0.4 μM of sense and antisense primers, 0.5X GC-rich solution and 1 unit of FastStart TaqDNA Polymerase (Roche Diagnostics, Mannheim, Germany). Reaction mixtures were hot-started at 95°C for 5 min. Amplification was performed in a Mastercycler gradient (Eppendorf) for 30 cycles (1 min at 95°C, 30 sec at 65°C (methylated sequence) and 62°C (unmethylated sequence) and 30 sec at 72°C, followed by a final extension of 5 min at 72°C. 25 microliters of PCR product were electrophoresed in 1.5% agarose gel, stained with ethidium bromide, and photographed under UV light (Figure 1. ). To confirm complete sodium bisulfite modification, the three differences in the PCR products of methylated and unmethylated bands were cut from the agarose gel, purified and sequenced. A representative chromagram of the sequencing results is shown in Figure 2 .
BRCA1 expression analysis by quantitative real-time reverse transcription-PCR
Alterations in BRCA1 mRNA expression levels were analyzed by LightCycler Instrument (Roche Applied Science). The reaction mixture was 20 ng of template cDNA, 1x LightCycler FastStart DNA Master SYBR Green I (Roche Applied Science, Germany), 4 mM MgCl2 and 0.5 μM forward and reverse primers in a final volume of 10 μl. The primer sequences were designed by Primer3 program, forward F-BRCA1 (5'-AAG ACA GAG CCC CAG AGT CA -3') and reverse R-BRCA1 (5'-CCC TGC TCA CAC TTT CTT CC -3'. β-globin housekeeping gene was used as an endogenous reference to obtain relative expression values ( Figure 3 ). PCR was started at 95°C for 5 min (to activate the FastStartTaq), followed by 40-cycle amplification (95°C for 10 s, 62°C for 30 s, and 72°C for 30 s). After the PCR, each amplification reaction was checked using a dissociation curve. PCR product purity was checked by 1.5% agarose gel electrophoresis, stained with ethidium bromide, and photographed under UV light. Relative gene expression level was determined as previously described by Livak and Schmittgen, 2001. The cutoff values for gene expression were adopted from median expression levels. Tumor gene expression <1.5fold was assigned as under-expression for BRCA1.
Statistical analysis
The association between BRCA1 hypermethylation, BRCA1 mRNA expression level, and clinicopathological characteristics--age at diagnosis, tumor size, histological grade, axillary lymph node-status, number of lymph nodes, staging, triple-negative breast tumor--was examined statistically by chi-square test. P value < 0.05 was considered a significant correlation.
Results
Methylation-specific PCR was used to examine 61 invasive ductal breast carcinomas for aberrant methylation status of the BRCA1 gene. The results revealed BRCA1 hypermethylation in 15 of 61 (24.6%) tumor samples. A significant association was observed between BRCA1 hypermethylation and tumor grade III, a high frequency of stage IIB with P value 0.04 and 0.02, respectively, as well as triple-negative tumor (OR= 3.64, 95%CI =1.1-12.3, p=0.03) ( Table I) .
Complete of sodium bisulfite modification was confirmed. The three different PCR products from the methylated and unmethylated bands were cut from the agarose gel, purified, and sequenced. The representative chromagram shows that cytosine residue from the CpG DOI:http://dx.doi.org/10.7314/APJCP.2014.15.24.10585 Clinicopathological Significance of BRCA1 Promoter Hypermethylation in Thai Breast Cancer Patients regions of the methylated PCR band remained unchanged. However, thymine-residue substitution was found in the unmethylated PCR band of the BRCA1 promoter region (Figure 2) . To assess the promoter hypermethylation status of BRCA1 effect on mRNA expression level, 45 breast tumors and their corresponding normal breast tissues were examined by quantitative real-time reverse transcription-PCR. Of 45 cases, 7 (15.6%) showed BRCA1 underexpression. A negative correlation between BRCA1 promoter hypermethylation and BRCA1 under-expression was found (Table I) . No association was found between BRCA1 under-expression and the clinicopathological features of breast-cancer patients (Table II) .
Discussion
Several studies have reported BRCA1 promoter hypermethylation in breast cancer; however, its mechanism in the pathogenesis of breast cancer is not yet clearly understood. Our study found BRCA1 hypermethylation associated significantly with tumor grade III, with a high frequency of stage IIB. This suggests that BRCA1 methylation is involved in late-stage progression among breast-cancer patients. Likewise, the study by Wei et al., 2005 suggested a role for BRCA1 methylation in the aggressiveness of breast carcinomas, and that BRCA1 methylated tumors were found mainly in tumor grade III rather than grades I and II (Birgisdottir et al., 2006; Gacem et al., 2012) .
The study also found that methylated BRCA1 correlated significantly with breast cancer subtype triple-negative (ER-, PR-and HER2-) tumor. This type of tumor is known to have a poor prognosis and to be more aggressive than hormone receptor-positive cancers (Camirand et al., 2013) . The present study indicated that aberrant BRCA1 methylation status was associated with the pathogenesis of breast-cancer subtype. Similarly, several studies have shown that BRCA1 methylation correlates with triple-negative breast tumors (Galizia et al., 2010; Stefansson et al., 2011; Gacem et al., 2012) .
In previous studies, the loss of gene expression in breast cancer was, often related to BRCA1 promoter hypermethylation. For example, several studies showed that BRCA1 promoter methylation is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens, and also with reduced protein levels in breast-cancer cell lines and sporadic breast carcinomas (Thompson et al., 1995; Sourvinos et al., 1998; Baldwin et al., 2000; Niwa et al., 2000; Rice et al., 2000; Matros et al., 2005; Mirza et al., 2007; Bal et al., 2012) . The present study showed that 7 of 45 cases (15.6%) referred to BRCA1 under-expression, of which only 1 (14.0%) case with BRCA1 hypermethylation showed reduced gene expression, and another 6 (86.0%) cases demonstrated BRCA1 unmethylation. Indicating that methylation was not the sole mechanism accounting for reduced BRCA1 protein expression (Sharma et al., 2010) . Therefore, multiple mechanisms effect the inactivation of BRCA1 function in breast cancer (Rice et al., 2000) . Several studies have demonstrated that mutations, loss of heterozygosity, and deletions, can also suppress BRCA1 expression in invasive sporadic breast tumors (Birgisdottir et al., 2006) . However, our findings demonstrated that BRCA1 underexpression did not correlate significantly with BRCA1 hypermethylation in breast-cancer patients. In consistent with our study, Pal et al., 2010 reported a negative correlation between methylation status and transcript expression levels for BRCA1 CpG sites in sporadic breast cancer, and that BRCA1 promoter methylation was not associated with loss of protein expression (Sharma et al., 2010) . DOI:http://dx.doi.org/10.7314/APJCP.2014.15.24.10585 Clinicopathological Significance of BRCA1 Promoter Hypermethylation in Thai Breast Cancer Patients In conclusion, our findings suggest that aberrant BRCA1 promoter hypermethylation is associated with tumor grade, late stage, and breast cancer subtype triplenegative tumor. This finding indicates that BRCA1 methylation is involved in the late-stage progression of breast-cancer and is a useful prognostic marker for breastcancer development. .
